Prescribing restrictions loom for hydroxyzine in Europe
This article was originally published in Scrip
Executive Summary
Prescribing restrictions are likely to be imposed on the antihistamine hydroxyzine in the EU after the European Medicines Agency's pharmacovigilance risk assessment committee (PRAC) said that measures should be taken to minimize the risk of heart rhythm problems associated with the product.